CASI Pharmaceuticals (CASIF) Total Liabilities (2020 - 2025)

CASI Pharmaceuticals has reported Total Liabilities for 6 years, with the latest figure at $62.9 million in Q4 2025.

• For the quarter ending Q4 2025, Total Liabilities rose 21.44% year-over-year to $62.9 million; the trailing twelve-month figure through Dec 2025 stood at $62.9 million (up 21.44% YoY), and the FY2025 full-year result was $62.9 million, up 21.44% from the prior year.
• Total Liabilities for Q4 2025 stood at $62.9 million, up from $53.1 million in the prior quarter.
• The five-year high for Total Liabilities was $62.9 million in Q4 2025, with the low at $24031.0 in Q2 2023.
• Historically, Total Liabilities has averaged $33.9 million across 5 years, with a median of $42.5 million in 2024.
• The largest YoY upside for Total Liabilities was 121821.89% in 2025 against a maximum downside of 99.89% in 2025.
• CASI Pharmaceuticals' Total Liabilities stood at $30.3 million in 2021, then dropped by 3.42% to $29.3 million in 2022, then soared by 74.4% to $51.1 million in 2023, then advanced by 1.41% to $51.8 million in 2024, then rose by 21.44% to $62.9 million in 2025.
• The last three Total Liabilities figures came in at $62.9 million (Q4 2025), $53.1 million (Q3 2025), and $51.5 million (Q2 2025), per Business Quant data.